. 2016 May 8;2016:4768728. doi: 10.1155/2016/4768728

Table 3.

CRC diagnosed within 24 months following gFOBT by baseline and subsequent screen, gFOBT result, sex, and anatomic CRC site.

	CRC following positive gFOBT	CRC following normal gFOBT (interval cancer)
Baseline gFOBT screen
CRC following baseline screen	762/1,243 (61.30%)^∗	481/1,243 (38.70%)^∗
CRC among males following baseline screen	501/755 (66.36%)^∗	254/755 (33.64%)^∗
CRC site among males
Distal anatomic CRC site	331/501 (66.07%)^∧	164/254 (64.57%)^∧
Another anatomic CRC site	170/501 (33.93%)^∧	90/254 (35.43%)^∧
CRC among females following baseline screen	261/488 (53.48%)^∗	227/488 (46.52%)^∗
CRC site among females
Distal anatomic CRC site	137/261 (52.49%)^∧	107/227 (47.14%)^∧
Another anatomic CRC site	124/261 (47.51%)^∧	120/227 (52.86%)^∧

Subsequent gFOBT screen
CRC following subsequent screen	171/348 (49.14%)^∗	177/348 (50.86%)^∗
CRC among males following subsequent screen	106/195 (54.36%)^∗	89/195 (45.64%)^∗
CRC site among males
Distal anatomic CRC site	75/106 (70.75%)^∧	57/89 (64.04%)^∧
Another anatomic CRC site	31/106 (29.25%)^∧	32/89 (35.96%)^∧
CRC among females following subsequent screen	65/153 (42.48%)^∗	88/153 (57.52%)^∗
CRC site among females
Distal anatomic CRC site	38/65 (58.46%)^∧	51/88 (57.95%)^∧
Another anatomic CRC site	27/65 (41.54%)^∧	37/88 (42.05%)^∧

^∗Row percent.

^∧Cell percent.